Markets:

Overview

News

Currencies

International

Treasuries

Exicure, Inc. - Common Stock (NQ:XCUR)

2.960 UNCHANGED

Streaming Delayed Price Updated: 3:59 PM EDT, Jun 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Exicure, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights

October 22, 2025

From Halper Sadeh LLC

Via Business Wire

Exicure, Inc. Reports Second Quarter 2025 Financial Results

August 08, 2025

From Exicure, Inc.

Via Business Wire

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements

August 04, 2025

From Exicure, Inc.

Via Business Wire

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

August 01, 2025

From Exicure, Inc.

Via Business Wire

Exicure, Inc. Reports First Quarter 2025 Financial Results

June 27, 2025

From Exicure, Inc.

Via Business Wire

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

May 28, 2025

From Exicure, Inc.

Via Business Wire

Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

May 05, 2025

From Exicure, Inc.

Via Business Wire

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

April 14, 2025

From Exicure, Inc.

Via Business Wire

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

April 11, 2025

From Exicure, Inc.

Via Business Wire

Exicure, Inc. Reports Full Year 2024 Financial Results

March 18, 2025

From Exicure, Inc.

Via Business Wire

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia

March 13, 2025

From Exicure, Inc.

Via Business Wire

CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

January 23, 2025

From Exicure, Inc.

Via Business Wire

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

December 26, 2024

From Exicure, Inc.

Via Business Wire

CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

December 21, 2024

From Exicure, Inc.

Via Business Wire

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

November 14, 2024

From Exicure, Inc.

Via Business Wire

Exicure, Inc. Receives Extension from Nasdaq Hearings Panel

September 18, 2024

From Exicure, Inc.

Via Business Wire

Exicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation

September 09, 2024

From Exicure, Inc.

Via Business Wire

Exicure, Inc. Announces 1-for-5 Reverse Stock Split

August 26, 2024

From Exicure, Inc.

Via Business Wire

Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting

August 19, 2024

From Exicure, Inc.

Via Business Wire

Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

August 15, 2024

From Exicure, Inc.

Via Business Wire

Exicure, Inc. Reports Second Quarter 2024 Financial Results

August 13, 2024

From Exicure, Inc.

Via Business Wire

Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics

August 08, 2024

From Exicure, Inc.

Via Business Wire

Exicure, Inc. Receives Positive Listing Determination from Nasdaq

August 01, 2024

From Exicure, Inc.

Via Business Wire

Exicure, Inc. Reports First Quarter 2024 Financial Results

June 17, 2024

From Exicure, Inc.

Via Business Wire

Exicure, Inc. Reports Full Year 2023 Financial Results

June 06, 2024

From Exicure, Inc.

Via Business Wire

Exicure, Inc. Received Nasdaq Notice of a Delisting Determination

May 23, 2024

From Exicure, Inc.

Via Business Wire

Exicure, Inc. Reports Third Quarter 2023 Financial Results

May 16, 2024

From Exicure, Inc.

Via Business Wire

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K

April 22, 2024

From Exicure, Inc.

Via Business Wire

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis

February 05, 2024

From Exicure, Inc.

Via Business Wire

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

November 28, 2023

From Exicure, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.